NCT04702503View on ClinicalTrials.gov

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

November 15, 2019

Study Completion Date

November 15, 2020

Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
DRUG

WP1220

Topical administration 2x daily for 84 consecutive days

Trial Locations (1)

Unknown

Medical University of Gdansk, Gdansk

Sponsors
All Listed Sponsors
lead

Moleculin Biotech, Inc.

INDUSTRY

NCT04702503 - Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) | Biotech Hunter | Biotech Hunter